SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox.
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.
Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox.
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer.
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities.
Shares of RxSight Inc. traded 7% higher after the company reported Q1/22 financial results which highlighted a 157% YoY increase in revenue and a 208% increase in unit sales of its Light Delivery Devices (LDD™s) utilized in cataract surgery procedures to implant its RxSight Light Adjustable Lens® (LAL), which it says is "the world's first and only adjustable intraocular lens (IOL) that is customized after cataract surgery."
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver.
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.
Silk Road Medical Inc. shares traded 12% higher after the company reported that the U.S. FDA granted expanded authorization for its ENROUTE® transcarotid stent system for use in preventing stroke in patients deemed to be at standard risk for adverse events from carotid endarterectomy.
After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'.
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.
Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies.
Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients.